EUVIMEDEUVIMED entdecken
Open Access

Risk of Relapse and Efficacy of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma

Risiko für Rezidiv und Wirksamkeit einer adjuvanten Chemotherapie bei lokalisiertem Appendicealkarzinom

Sacha El Khoury, Mohammad M Fanaeian, Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Jennifer Peterson, Emaan Haque, Nicholas Hornstein, Melissa W Taggart, Wai Chin Foo, Jarett Feldman, Nicole Aguirre und 17 weitere

JAMA Surgery · 01.11.2026 · 161 (11) · 1165

DOI: 10.1001/jamasurg.2026.4000 ↗

Auf einen Blick

Bei lokalisiertem Appendicealkarzinom war ein Rezidiv nach Resektion selten. Eine adjuvante Chemotherapie war nicht mit besserem rezidivfreiem oder Gesamtüberleben verbunden.

Fragestellung

Welche klinisch-pathologischen und genomischen Faktoren sind mit einem Rezidiv assoziiert, und hat adjuvante Chemotherapie bei lokalisiertem Appendicealkarzinom einen Nutzen?

Methode

Retrospektive Kohortenstudie mit Kaplan-Meier- und Cox-Modell; Daten von Januar 2000 bis Februar 2024, Validierung an einem zweiten Zentrum.

Ergebnisse

439 Patient:innen mit lokalisiertem AA; 202 wurden am UT MD Anderson operiert. Bei 19/202 (9,4 %) trat ein Rezidiv auf. Adjuvante Chemotherapie zeigte keinen Zusammenhang mit RFS oder OS.

Schlussfolgerung der Autor:innen

Rezidive nach Resektion lokalisierten AA waren selten. Molekulare Profile und histopathologischer Subtyp schärfen die Risikoeinschätzung; adjuvante Chemotherapie brachte keinen Nutzen.

Kernaussagen

  • Rezidiv bei 19/202 operierten Patient:innen (9,4 %)
  • Adjuvante Chemotherapie ohne Vorteil für RFS oder OS
  • Molekulare und histologische Merkmale verbesserten die Risikostratifizierung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Surgery, erschienen am 01.11.2026. Verfasst von Sacha El Khoury und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Appendiceal Neoplasms, Adenocarcinoma, Neoplasm Recurrence, Local. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Relapse risk and benefit of adjuvant chemotherapy after resection of appendiceal adenocarcinoma (AA) are uncertain.

Objective

To identify clinicopathologic and genomic factors associated with relapse and assess efficacy of adjuvant chemotherapy in localized AA. Design, Setting, and Participants This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling. It took place at the University of Texas MD (UT MD) Anderson Cancer Center with validation from Memorial Sloan Kettering Cancer Center (MSKCC). Participants included a complete localized cohort of 439 patients with stage I to III AA from UT MD Anderson, of whom 202 underwent surgery at UT MD Anderson and also included a validation cohort of 128 patients with stage II AA from MSKCC. Exposures Surgical resection with or without adjuvant chemotherapy. Main Outcomes and Measures Rate of recurrence, recurrence-free survival (RFS), and overall survival (OS).

Results

There were 439 patients with localized AA (median age, 56.5 [IQR, 22.2-83.7] years; 50% female and 50% male) managed at MD Anderson between January 2000 and February 2024. Of 202 MDA surgical patients, 19 (9.4%) had a relapse including 9 (6%) patients with stage II and 8 (19.5%) of patients stage III disease. Five-year OS was 95.7% without vs 77.2% with relapse (hazard ratio [HR], 5.50; 95% CI, 3.07-9.83; P < .001). Relative to goblet cell tumors, mucinous (HR, 5.60; 95% CI, 2.1-15; P < .001) and enteric-type (HR, 6.60; 95% CI, 2.9-15; P < .001) histologies were independently associated with relapse, as was pathologic T4 (HR, 3.30; 95% CI, 1.9-5.7; P < .001). Importantly, poor differentiation, perforation, lymphovascular invasion, and perineural invasion, known risk factors in colorectal cancer, were not significantly associated with relapse. For the complete localized cohort, adjuvant chemotherapy was not associated with improved RFS (univariate HR, 2.06; 95% CI, 1.36-3.13; P = .001 and multivariable HR, 0.98; 95% CI, 0.43-2.28; P = .90) or OS (univariate HR, 1.80; 95% CI, 1.0-3.2; P = .04 and multivariable HR, 0.71; 95% CI, 0.24-2.1; P = .53). TP53 mutation in goblet cell tumors (HR, 6.93; 95% CI, 1.50-31.00; P = .01) and GNAS mutation in nongoblet tumors (HR, 17.0; 95% CI, 3.09-93.3; P = .001) were associated with greater risk of relapse. Conclusions and Relevance These results demonstrate that relapse after resection of localized AA is uncommon. Molecular profiling and histopathologic subtype refine risk. Adjuvant chemotherapy were not associated with benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Appendiceal NeoplasmsAdenocarcinomaNeoplasm Recurrence, LocalHumansChemotherapy, AdjuvantFemaleRetrospective StudiesMaleMiddle AgedAgedAdultAged, 80 and overNeoplasm StagingAppendectomy

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • University of New Mexico Hospital, Albuquerque.
  • Department of Pathology, Division of Pathology-Lab Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

El Khoury, S., Fanaeian, M. M., Yousef, M., Yousef, A., Chowdhury, S., Peterson, J., Haque, E., Hornstein, N., Taggart, M. W., Foo, W. C., Feldman, J., Aguirre, N., Nash, G., Gowda, T., Karagkounis, G., Cercek, A., Vakiani, E., de Gonzalez, A. K., Beaty, K. A., …, & Shen, J. P. (2026). Risk of Relapse and Efficacy of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma. JAMA Surgery, 161(11), 1165. https://doi.org/10.1001/jamasurg.2026.4000

Vancouver

El Khoury S, Fanaeian MM, Yousef M, Yousef A, Chowdhury S, Peterson J, et al. Risk of Relapse and Efficacy of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma. JAMA Surgery. 2026;161(11):1165. doi:10.1001/jamasurg.2026.4000

BibTeX
@article{ElKhoury2026,
  author = {El Khoury, Sacha and Fanaeian, Mohammad M and Yousef, Mahmoud and Yousef, Abdelrahman and Chowdhury, Saikat and Peterson, Jennifer and Haque, Emaan and Hornstein, Nicholas and Taggart, Melissa W and Foo, Wai Chin and Feldman, Jarett and Aguirre, Nicole and Nash, Garrett and Gowda, Tina and Karagkounis, Georgios and Cercek, Andrea and Vakiani, Efsevia and de Gonzalez, Anne Koehne and Beaty, Karen A and Pattalachinti, Vinay and Overmann, Micheal and Scally, Christopher and Mansfield, Paul F and Song, Yun and White, Michael G and Helmink, Beth and Fournier, Keith F and Foote, Michael B and Shen, John Paul},
  title = {Risk of Relapse and Efficacy of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma},
  journal = {JAMA Surgery},
  year = {2026},
  volume = {161},
  number = {11},
  pages = {1165},
  doi = {10.1001/jamasurg.2026.4000}
}
Kostenlos starten →